OncoMatch/Clinical Trials/NCT06686108
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
Is NCT06686108 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Azacitidine (AZA) Days 1 - 5 and Decitabine (DAC) for t-cell acute lymphoblastic leukemia.
Treatment: Azacitidine (AZA) Days 1 - 5 · Decitabine (DAC) · Venetoclax — This study is a prospective, phase II clinical trial with the primary objective of assessing the effectiveness of demethylating agents combined with venetoclax in the prevention of recurrence after allogeneic hematopoietic stem cell transplantation (allo-HSCT) of high risk T-lymphoblastic lymphoma/leukemia (T-LBL/ALL) patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Allowed: FLT3 mutation
gene mutations involving myeloid related genes, RAS/PI3K/AKT, JAK/STAT signaling pathway, and epigenetics, such as FLT3, NRAS/KRAS, PTEN, IL7R, JAK1, JAK3, DNMT3A, IDH1, IDH2; TP53, BCL2 mutations
Allowed: NRAS mutation
gene mutations involving myeloid related genes, RAS/PI3K/AKT, JAK/STAT signaling pathway, and epigenetics, such as FLT3, NRAS/KRAS, PTEN, IL7R, JAK1, JAK3, DNMT3A, IDH1, IDH2; TP53, BCL2 mutations
Allowed: KRAS mutation
gene mutations involving myeloid related genes, RAS/PI3K/AKT, JAK/STAT signaling pathway, and epigenetics, such as FLT3, NRAS/KRAS, PTEN, IL7R, JAK1, JAK3, DNMT3A, IDH1, IDH2; TP53, BCL2 mutations
Allowed: PTEN mutation
gene mutations involving myeloid related genes, RAS/PI3K/AKT, JAK/STAT signaling pathway, and epigenetics, such as FLT3, NRAS/KRAS, PTEN, IL7R, JAK1, JAK3, DNMT3A, IDH1, IDH2; TP53, BCL2 mutations
Allowed: IL7R mutation
gene mutations involving myeloid related genes, RAS/PI3K/AKT, JAK/STAT signaling pathway, and epigenetics, such as FLT3, NRAS/KRAS, PTEN, IL7R, JAK1, JAK3, DNMT3A, IDH1, IDH2; TP53, BCL2 mutations
Allowed: JAK1 mutation
gene mutations involving myeloid related genes, RAS/PI3K/AKT, JAK/STAT signaling pathway, and epigenetics, such as FLT3, NRAS/KRAS, PTEN, IL7R, JAK1, JAK3, DNMT3A, IDH1, IDH2; TP53, BCL2 mutations
Allowed: JAK3 mutation
gene mutations involving myeloid related genes, RAS/PI3K/AKT, JAK/STAT signaling pathway, and epigenetics, such as FLT3, NRAS/KRAS, PTEN, IL7R, JAK1, JAK3, DNMT3A, IDH1, IDH2; TP53, BCL2 mutations
Allowed: DNMT3A mutation
gene mutations involving myeloid related genes, RAS/PI3K/AKT, JAK/STAT signaling pathway, and epigenetics, such as FLT3, NRAS/KRAS, PTEN, IL7R, JAK1, JAK3, DNMT3A, IDH1, IDH2; TP53, BCL2 mutations
Allowed: IDH1 mutation
gene mutations involving myeloid related genes, RAS/PI3K/AKT, JAK/STAT signaling pathway, and epigenetics, such as FLT3, NRAS/KRAS, PTEN, IL7R, JAK1, JAK3, DNMT3A, IDH1, IDH2; TP53, BCL2 mutations
Allowed: IDH2 mutation
gene mutations involving myeloid related genes, RAS/PI3K/AKT, JAK/STAT signaling pathway, and epigenetics, such as FLT3, NRAS/KRAS, PTEN, IL7R, JAK1, JAK3, DNMT3A, IDH1, IDH2; TP53, BCL2 mutations
Allowed: TP53 mutation
gene mutations involving myeloid related genes, RAS/PI3K/AKT, JAK/STAT signaling pathway, and epigenetics, such as FLT3, NRAS/KRAS, PTEN, IL7R, JAK1, JAK3, DNMT3A, IDH1, IDH2; TP53, BCL2 mutations
Allowed: BCL2 mutation
gene mutations involving myeloid related genes, RAS/PI3K/AKT, JAK/STAT signaling pathway, and epigenetics, such as FLT3, NRAS/KRAS, PTEN, IL7R, JAK1, JAK3, DNMT3A, IDH1, IDH2; TP53, BCL2 mutations
Allowed: MYC rearrangement
t (8; 14) (q24; q11)/MYC rearrangement
Allowed: TCR-LYL1 fusion
t (7; 19) (q34; p13)/TCR-LYL1
Allowed: TCR-MEF2C fusion
TCR-MEF2C
Allowed: NOTCH1 mutation
NOTCH1
Allowed: FBXW7 mutation
FBXW7
Allowed: PHF6 mutation
PHF6
Allowed: EP300 mutation
EP300
Allowed: IKZF1 mutation
IKZF1
Allowed: DNMT3A mutation
DNTM3A
Allowed: IDH1 mutation
IDH1
Allowed: IDH2 mutation
IDH2
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: allogeneic hematopoietic stem cell transplant
Patients with allo-HSCT due to T-LBL/ALL
Cannot have received: BCL-2 inhibitor
Exception: resistant to BCL-2 inhibitors before transplantation, if the disease progresses during the application process, or if 3-4 courses of induction therapy containing BCL2 inhibitors do not improve
For those who are resistant to BCL-2 inhibitors before transplantation, if the disease progresses during the application process, or if 3-4 courses of induction therapy containing BCL2 inhibitors do not improve
Lab requirements
Blood counts
ANC ≥ 1.0 × 10^9/L, PLT ≥ 50 × 10^9/L
Kidney function
endogenous creatinine clearance rate (Ccr) less than 50mL/min or 1.5 times the normal value of blood creatinine [excluded]
Liver function
AST/ALT more than 3 times the normal value or direct bilirubin more than 3 times normal value [excluded]
Blood routine: ANC ≥ 1.0 × 10^9/L, PLT ≥ 50 × 10^9/L. AST/ALT more than 3 times the normal value or direct bilirubin more than 3 times normal value [excluded]. Endogenous creatinine clearance rate (Ccr) less than 50mL/min or 1.5 times the normal value of blood creatinine [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06686108 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BCL-2 inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 55 years or younger and at least 14 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages